First Pharmaceutical Holdings announced that revenue for the third quarter of 2026 was 65.2347 million yuan, net profit of 165.17,500 yuan, after deducting non-net profit of 139.1331 million yuan; revenue for the first three quarters of 2026 was 93.2347 million yuan, up 4,561.73% year-on-year, with a net profit loss of 44.542 million yuan, net profit loss of 53.27 million yuan. According to the announcement, milestone revenue and cooperative revenue from cooperative R&D projects have increased, and commercial supply and sales of cantertinib granules have begun, driving revenue growth.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.